Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Colorectal Cancer
- Sponsor
- Andrew Kennedy
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.
- Last Updated
- 13 years ago
Overview
Brief Summary
Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks follow up.
Detailed Description
Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks follow up. Objectives: Independent data collection and reporting of pre treatment and 12 week post treatment clinical, radiographic and radiation parameters and outcomes in patients treated in the USA from 2002-2010. Data beyond 12 weeks will be collected and highly desirable, however as a minimum all patients will have 12 week follow up.
Investigators
Andrew Kennedy
Principal Investigator and Sponsor-Investigator
Sarah Cannon
Eligibility Criteria
Inclusion Criteria
- •Patients who received 90Y resin microsphere radioembolization for metastatic colorectal cancer with liver metastases between November 2010 and March 2011 in the USA. Patients must have at least 12 weeks of follow up.
Exclusion Criteria
- •Patients who received glass 90Y microsphere radioembolization for metastatic colorectal liver metastases.
Outcomes
Primary Outcomes
Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.
Time Frame: 3 months
Multiple systems monitored for side effects possibly related to liver radiotherapy.
Secondary Outcomes
- Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans.(3 months)